Monday, January 23, 2012 8:32:22 AM
Watch inventory? Why Qiagen May Be About to Take Off
By Seth Jayson | More Articles
January 11, 2012 |
Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It’s a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Qiagen (Nasdaq: QGEN ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Qiagen doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 2.8%, and inventory increased 10.9%. Over the sequential quarterly period, the trend looks OK but not great. Revenue grew 2.4%, and inventory grew 4.4%.
Advanced inventory
I don’t stop my checkup there, because the type of inventory can matter even more than the overall quantity. There’s even one type of inventory bulge we sometimes like to see. You can check for it by examining the quarterly filings to evaluate the different kinds of inventory: raw materials, work-in-progress inventory, and finished goods. (Some companies report the first two types as a single category.)
A company ramping up for increased demand may increase raw materials and work-in-progress inventory at a faster rate when it expects robust future growth. As such, we might consider oversized growth in those categories to offer a clue to a brighter future, and a clue that most other investors will miss. We call it "positive inventory divergence.”
On the other hand, if we see a big increase in finished goods, that often means product isn’t moving as well as expected, and it’s time to hunker down with the filings and conference calls to find out why.
What’s going on with the inventory at Qiagen? I chart the details below for both quarterly and 12-month periods.
Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.
Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FQ = fiscal quarter.
Let's dig into the inventory specifics. On a trailing-12-month basis, work-in-progress inventory was the fastest-growing segment, up 16.9%. On a sequential-quarter basis, finished goods inventory was the fastest-growing segment, up 7.7%. That can be a warning sign, so investors should check in with Qiagen's filings to make sure there's a good reason for packing the storeroom for this period. Although Qiagen shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.
Foolish bottom line
When you’re doing your research, remember that aggregate numbers such as inventory balances often mask situations that are more complex than they appear. Even the detailed numbers don’t give us the final word. When in doubt, listen to the conference call, or contact investor relations. What at first looks like a problem may actually signal a stock that will provide the market's best returns. And what might look hunky-dory at first glance could actually be warning you to cut your losses before the rest of the Street wises up.
I run these quick inventory checks every quarter. To stay on top of inventory and other tell-tale metrics at your favorite companies, add them to your free watchlist, and we’ll deliver our latest coverage right to your inbox.
http://www.fool.com/investing/general/2012/01/12/why-qiagen-may-be-about-to-take-off.aspx
By Seth Jayson | More Articles
January 11, 2012 |
Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It’s a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Qiagen (Nasdaq: QGEN ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Qiagen doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 2.8%, and inventory increased 10.9%. Over the sequential quarterly period, the trend looks OK but not great. Revenue grew 2.4%, and inventory grew 4.4%.
Advanced inventory
I don’t stop my checkup there, because the type of inventory can matter even more than the overall quantity. There’s even one type of inventory bulge we sometimes like to see. You can check for it by examining the quarterly filings to evaluate the different kinds of inventory: raw materials, work-in-progress inventory, and finished goods. (Some companies report the first two types as a single category.)
A company ramping up for increased demand may increase raw materials and work-in-progress inventory at a faster rate when it expects robust future growth. As such, we might consider oversized growth in those categories to offer a clue to a brighter future, and a clue that most other investors will miss. We call it "positive inventory divergence.”
On the other hand, if we see a big increase in finished goods, that often means product isn’t moving as well as expected, and it’s time to hunker down with the filings and conference calls to find out why.
What’s going on with the inventory at Qiagen? I chart the details below for both quarterly and 12-month periods.
Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.
Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FQ = fiscal quarter.
Let's dig into the inventory specifics. On a trailing-12-month basis, work-in-progress inventory was the fastest-growing segment, up 16.9%. On a sequential-quarter basis, finished goods inventory was the fastest-growing segment, up 7.7%. That can be a warning sign, so investors should check in with Qiagen's filings to make sure there's a good reason for packing the storeroom for this period. Although Qiagen shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.
Foolish bottom line
When you’re doing your research, remember that aggregate numbers such as inventory balances often mask situations that are more complex than they appear. Even the detailed numbers don’t give us the final word. When in doubt, listen to the conference call, or contact investor relations. What at first looks like a problem may actually signal a stock that will provide the market's best returns. And what might look hunky-dory at first glance could actually be warning you to cut your losses before the rest of the Street wises up.
I run these quick inventory checks every quarter. To stay on top of inventory and other tell-tale metrics at your favorite companies, add them to your free watchlist, and we’ll deliver our latest coverage right to your inbox.
http://www.fool.com/investing/general/2012/01/12/why-qiagen-may-be-about-to-take-off.aspx
Recent QGEN News
- QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak • Business Wire • 05/28/2026 08:05:00 PM
- QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows • Business Wire • 05/20/2026 08:05:00 PM
- QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA • Business Wire • 05/19/2026 08:05:00 PM
- QIAGEN plant die Ernennung von Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, setzt die Neuausrichtung der Aufsichtsratsstruktur fort und schlägt höhere Kapitalrückzahlungen auf der Hauptversammlung 2026 vor • Business Wire • 05/12/2026 06:00:00 AM
- QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting • Business Wire • 05/12/2026 06:00:00 AM
- QIAGEN plant Einführung eines neuen, vollautomatisierten Sample-to-Insight-Workflows und eines KI-gestützten Tools zur Risikostratifizierung als Weiterentwicklung seines QuantiFERON-Tests zum Nachweis latenter Tuberkulose • Business Wire • 05/07/2026 10:00:00 AM
- QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing • Business Wire • 05/07/2026 10:00:00 AM
- QIAGEN Reports Full Results for Q1 2026 • Business Wire • 05/06/2026 08:05:00 PM
- QIAGEN meldet vollständige Ergebnisse für das erste Quartal 2026 • Business Wire • 05/06/2026 08:05:00 PM
- QIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026: Bereinigter Gewinn je Aktie entspricht bei gemischten Umsatztrends den Erwartungen; Jahresprognose 2026 aktualisiert • Business Wire • 04/27/2026 08:16:00 PM
- QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook • Business Wire • 04/27/2026 08:16:00 PM
- QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 • Business Wire • 04/16/2026 08:05:00 PM
- QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel • Business Wire • 04/14/2026 08:05:00 PM
- Qiagen Announces Form 20-F Annual Report Filing for 2025 Results • Business Wire • 03/20/2026 11:30:00 AM
- QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention • Business Wire • 03/19/2026 08:05:00 PM
- QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor • Business Wire • 03/19/2026 08:05:00 PM
- QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System • Business Wire • 03/10/2026 09:05:00 PM
- Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery • Business Wire • 02/19/2026 01:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/06/2026 05:08:56 PM
- QIAGEN übertrifft Prognose für das vierte Quartal 2025 dank seiner Wachstumsträger • Business Wire • 02/04/2026 09:05:00 PM
- QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars • Business Wire • 02/04/2026 09:05:00 PM
- QIAGEN präsentiert sein Hochdurchsatz-Automationssystem QIAsprint Connect für Labore weltweit auf der SLAS 2026 • Business Wire • 02/03/2026 09:05:00 PM
- QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 • Business Wire • 02/03/2026 09:05:00 PM
- QIAGEN Appoints Mark Stevenson to Supervisory Board • Business Wire • 01/26/2026 09:05:00 PM
- QIAGEN beruft Mark Stevenson in den Aufsichtsrat • Business Wire • 01/26/2026 09:05:00 PM

